Wood remains committed to Numinus over the long term and will continue as the Company's Chief Medical Officer through the integration of Novamind, though with reduced office hours. Evan Wood, Chief Medical Officer, will now be able to continue in his role in a reduced capacity, in order to enable him to maintain his important advocacy, clinical and teaching work. Tan has been instrumental in Numinus' growth, and joined the Company in 2019.Īs a result of the increased medical and research expertise added to Numinus' expanded executive team, Dr. Tan will oversee all Company operations and will lead strategic directives to drive revenue growth through future footprint and product line expansions. Numinus is also pleased to announce that as a result of his growing responsibilities, Michael Tan has been promoted to President and Chief Operating Officer. He is a graduate of the California Institute of Integrative Studies' Certification of Psychedelic Therapy and Research program. Thielking was director of psycho-oncology at the University of Utah Huntsman Cancer Institute for five years and previously an associate professor in the department of psychiatry at the University of Utah. He has extensive experience with creating group therapy interventions for patients with serious illness and has successfully integrated ketamine-assisted psychotherapy services within an academic outpatient oncology clinic for cancer patients with depression. He is the principal investigator for a psilocybin-enhanced group psychotherapy intervention for cancer patients with depression and a co-investigator on a study for ketamine-assisted psychotherapy for opioid use disorder. Thielking was most recently Chief Scientific Officer at Novamind and is board certified in psychiatry, hospice and palliative medicine, and integrative medicine.
Robison is an adjunct professor at both the University of Utah and Brigham Young University.ĭr. Robison has guided thousands of ketamine-assisted therapy sessions and hundreds of Spravato™ dosing sessions.
Robison also led a pivotal intravenous ketamine study for treatment-resistant depression by Janssen, leading up to that company's recent FDA-approval of Spravato™. As an early adopter and researcher of the use of ketamine in psychiatry, Dr. He was previously a coordinating investigator for a study on MDMA-assisted therapy for eating disorders, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He is a board-certified psychiatrist and co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading center for the treatment of eating disorders. Robison was most recently Chief Medical Officer at Novamind. On a proforma basis, the combined business generated C$11.9 million of annual revenues (trailing four quarters reported, as at June 10, 2022).ĭr. The transaction has also provided a strong US platform for potential continued growth in partnership and acquisition opportunities. Numinus and Novamind clients will benefit from access to a greater variety of services and treatments over the coming months, including the expansion of virtual therapy services at US-based clinics and increased group therapy offerings in Canada. This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues. As a result of the acquisition, Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies. ("Novamind") has completed, following Novamind's receipt of a final order from the BC Supreme Court. ("Numinus", the "Company") NUMI NUMIF is pleased to announce the acquisition (the "Transaction") of Novamind Inc. VANCOUVER, BC, J/CNW/ - Numinus Wellness Inc. Michael Tan has been promoted to President and Chief Operating Officer.Reid Robison has been appointed Chief Clinical Officer and Paul Thielking has been appointed Chief Science Officer.As a result of the acquisition, Novamind has ceased trading on the Canadian Securities Exchange (CSE).
Novamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind share.Transaction has completed following shareholder and court approvals.
0 kommentar(er)
